RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Karam F. Soliman to Lipopolysaccharides

This is a "connection" page, showing publications Karam F. Soliman has written about Lipopolysaccharides.
Connection Strength

2.566
  1. Hilliard A, Mendonca P, Soliman KFA. Involvement of NF?B and MAPK signaling pathways in the preventive effects of Ganoderma lucidum on the inflammation of BV-2 microglial cells induced by LPS. J Neuroimmunol. 2020 08 15; 345:577269.
    View in: PubMed
    Score: 0.678
  2. Mendonca P, Taka E, Bauer D, Reams RR, Soliman KFA. The attenuating effects of 1,2,3,4,6 penta-O-galloyl-?-d-glucose on pro-inflammatory responses of LPS/IFN?-activated BV-2 microglial cells through NF?B and MAPK signaling pathways. J Neuroimmunol. 2018 11 15; 324:43-53.
    View in: PubMed
    Score: 0.603
  3. Barber K, Mendonca P, Evans JA, Soliman KFA. Antioxidant and Anti-Inflammatory Mechanisms of Cardamonin through Nrf2 Activation and NF-kB Suppression in LPS-Activated BV-2 Microglial Cells. Int J Mol Sci. 2023 Jun 29; 24(13).
    View in: PubMed
    Score: 0.210
  4. Cobourne-Duval MK, Taka E, Mendonca P, Soliman KFA. Thymoquinone increases the expression of neuroprotective proteins while decreasing the expression of pro-inflammatory cytokines and the gene expression NF?B pathway signaling targets in LPS/IFN? -activated BV-2 microglia cells. J Neuroimmunol. 2018 07 15; 320:87-97.
    View in: PubMed
    Score: 0.147
  5. Messeha SS, Zarmouh NO, Mendonca P, Kolta MG, Soliman KFA. The attenuating effects of plumbagin on pro-inflammatory cytokine expression in LPS-activated BV-2 microglial cells. J Neuroimmunol. 2017 12 15; 313:129-137.
    View in: PubMed
    Score: 0.141
  6. Mendonca P, Taka E, Bauer D, Cobourne-Duval M, Soliman KF. The attenuating effects of 1,2,3,4,6 penta-O-galloyl-?-d-glucose on inflammatory cytokines release from activated BV-2 microglial cells. J Neuroimmunol. 2017 04 15; 305:9-15.
    View in: PubMed
    Score: 0.134
  7. Mazzio EA, Bauer D, Mendonca P, Taka E, Soliman KF. Natural product HTP screening for attenuation of cytokine-induced neutrophil chemo attractants (CINCs) and NO2- in LPS/IFN? activated glioma cells. J Neuroimmunol. 2017 01 15; 302:10-19.
    View in: PubMed
    Score: 0.133
  8. Mazzio EA, Li N, Bauer D, Mendonca P, Taka E, Darb M, Thomas L, Williams H, Soliman KF. Natural product HTP screening for antibacterial (E.coli 0157:H7) and anti-inflammatory agents in (LPS from E. coli O111:B4) activated macrophages and microglial cells; focus on sepsis. BMC Complement Altern Med. 2016 Nov 15; 16(1):467.
    View in: PubMed
    Score: 0.133
  9. Cobourne-Duval MK, Taka E, Mendonca P, Bauer D, Soliman KF. The Antioxidant Effects of Thymoquinone in Activated BV-2 Murine Microglial Cells. Neurochem Res. 2016 Dec; 41(12):3227-3238.
    View in: PubMed
    Score: 0.131
  10. Taka E, Mazzio EA, Goodman CB, Redmon N, Flores-Rozas H, Reams R, Darling-Reed S, Soliman KF. Anti-inflammatory effects of thymoquinone in activated BV-2 microglial cells. J Neuroimmunol. 2015 Sep 15; 286:5-12.
    View in: PubMed
    Score: 0.121
  11. Mazzio EA, Soliman KF. Glioma cell antioxidant capacity relative to reactive oxygen species produced by dopamine. J Appl Toxicol. 2004 Mar-Apr; 24(2):99-106.
    View in: PubMed
    Score: 0.055
  12. Mazzio E, Becker A, Soliman KF. Inflammation and inducible nitric oxide synthase have no effect on monoamine oxidase activity in glioma cells. Biochem Pharmacol. 2003 May 15; 65(10):1719-27.
    View in: PubMed
    Score: 0.052
  13. Gangapuram M, Mazzio E, Eyunni S, Soliman KF, Redda KK. Synthesis and biological evaluation of substituted N-[3-(1H-pyrrol-1-yl)methyl]-1,2,5,6-tetrahydropyridin-1-yl]benzamide/benzene sulfonamides as anti-inflammatory agents. Arch Pharm (Weinheim). 2014 May; 347(5):360-9.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support